Curis, Inc., a biotechnology company, focuses on the development and commercialization of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include CUDC-907, an oral dual inhibitor of HDAC and PI3K enzymes, which is in Phase II clinical trial for the treatment of patients with MYC-altered diffuse large B-cell lymphoma and solid tumors; CA-170, an oral small molecule drug candidate that is in Phase I clinical trial for treating patients with advanced solid tumors and lymphomas; CA-4948, an oral small molecule drug candidate, which is in Phase I clinical trial for the treatment of non-hodgkin lymphomas; and CA-327, an oral small molecule drug candidate that is in preclinical stage for the treatment of cancers. The company has collaboration agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway inhibitor for the treatment of advanced basal cell carcinoma; and with Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology. Curis, Inc. was founded in 2000 and is headquartered in Lexington, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:CRIS
CUSIP23126910
Phone617-503-6500
Debt
Debt-to-Equity Ratio4.43
Current Ratio3.01
Quick Ratio3.01
Price-To-Earnings
Trailing P/E Ratio-0.92
Forward P/E Ratio-1.40
P/E GrowthN/A
Sales & Book Value
Annual Sales$9.90 million
Price / Sales5.53
Cash FlowN/A
Price / CashN/A
Book Value$0.73 per share
Price / Book2.26
Profitability
EPS (Most Recent Fiscal Year)($1.80)
Net Income$-53,310,000.00
Net Margins-407.29%
Return on Equity-225.77%
Return on Assets-63.38%
Miscellaneous
Employees55
Outstanding Shares33,180,000
Market Cap$53.75 million
Curis (NASDAQ:CRIS) Frequently Asked Questions
What is Curis' stock symbol?
Curis trades on the NASDAQ under the ticker symbol "CRIS."
When did Curis' stock split? How did Curis' stock split work?
Shares of Curis reverse split before market open on Wednesday, May 30th 2018. The 1-5 reverse split was announced on Tuesday, May 22nd 2018. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, May 29th 2018. An investor that had 100 shares of Curis stock prior to the reverse split would have 20 shares after the split.
How were Curis' earnings last quarter?
Curis, Inc. (NASDAQ:CRIS) posted its quarterly earnings data on Thursday, August, 2nd. The biotechnology company reported ($0.26) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.41) by $0.15. The biotechnology company earned $2.36 million during the quarter, compared to analyst estimates of $2.41 million. Curis had a negative return on equity of 225.77% and a negative net margin of 407.29%. View Curis' Earnings History.
When is Curis' next earnings date?
What price target have analysts set for CRIS?
4 brokerages have issued 1-year price targets for Curis' shares. Their forecasts range from $8.00 to $35.00. On average, they anticipate Curis' stock price to reach $24.3333 in the next year. This suggests a possible upside of 1,374.7% from the stock's current price. View Analyst Price Targets for Curis.
What is the consensus analysts' recommendation for Curis?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Curis in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Curis.
Who are some of Curis' key competitors?
Some companies that are related to Curis include Compugen (CGEN), Krystal Biotech (KRYS), Eiger Biopharmaceuticals (EIGR), Fennec Pharmaceuticals (FENC), Pluristem Therapeutics (PSTI), Organovo (ONVO), Cidara Therapeutics (CDTX), Champions Oncology (CSBR), Aptose Biosciences (APTO), Brainstorm Cell Therapeutics (BCLI), Aevi Genomic Medicine (GNMX), Applied Genetic Technologies (AGTC), TRACON Pharmaceuticals (TCON), BioCardia (BCDA) and Oncobiologics (ONS).
Who are Curis' key executives?
Curis' management team includes the folowing people:
- Dr. Ali Fattaey, CEO, Pres & Director (Age 53)
- Mr. James E. Dentzer, COO, CFO & Chief Admin. Officer (Age 51)
- Dr. David Tuck, Sr. VP & Chief Medical Officer (Age 66)
- Mr. Mark W. Noel, VP of Technology Management & Intellectual Property (Age 59)
- Dr. Minji Kim Ph.D., MBA, VP of Corp. & Bus. Devel.
Has Curis been receiving favorable news coverage?
News coverage about CRIS stock has been trending somewhat positive recently, Accern Sentiment reports. The research firm ranks the sentiment of media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Curis earned a media and rumor sentiment score of 0.18 on Accern's scale. They also assigned headlines about the biotechnology company an impact score of 46.57 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next several days. View Recent Headlines for Curis.
Who are Curis' major shareholders?
Curis' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (2.43%), Renaissance Technologies LLC (1.43%), GSA Capital Partners LLP (1.03%), Millennium Management LLC (0.94%), Paloma Partners Management Co (0.39%) and Bain Capital Public Equity Management LLC (0.30%). Company insiders that own Curis stock include Ali PhD Fattaey, James R Mcnab and Marc Rubin. View Institutional Ownership Trends for Curis.
Which institutional investors are selling Curis stock?
CRIS stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Renaissance Technologies LLC, GSA Capital Partners LLP, Northern Trust Corp and Bain Capital Public Equity Management LLC. View Insider Buying and Selling for Curis.
Which institutional investors are buying Curis stock?
CRIS stock was purchased by a variety of institutional investors in the last quarter, including Millennium Management LLC, Paloma Partners Management Co and LMR Partners LLP. Company insiders that have bought Curis stock in the last two years include Ali PhD Fattaey and Marc Rubin. View Insider Buying and Selling for Curis.
How do I buy shares of Curis?
Shares of CRIS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Curis' stock price today?
One share of CRIS stock can currently be purchased for approximately $1.65.
How big of a company is Curis?
Curis has a market capitalization of $53.75 million and generates $9.90 million in revenue each year. The biotechnology company earns $-53,310,000.00 in net income (profit) each year or ($1.80) on an earnings per share basis. Curis employs 55 workers across the globe.
How can I contact Curis?
Curis' mailing address is 4 MAGUIRE ROAD, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 617-503-6500 or via email at [email protected]
MarketBeat Community Rating for Curis (NASDAQ CRIS)
MarketBeat's community ratings are surveys of what our community members think about Curis and other stocks. Vote "Outperform" if you believe CRIS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRIS will underperform the S&P 500 over the long term. You may vote once every thirty days.
